Infections in Chronic Lymphocytic Leukemia: Risk Factors, and Impact on Survival, and Treatment

References

• Chapel H. M., Bunch C. Mechanisms of infection in chronic lymphocytic leukemia. Semin. Hematol. 1987; 24: 291–296
   PubMed Web of Science ®Google Scholar
• Bunch C. Management of infection in chronic lymphocytic leukaemia. Chronic Lymphocytic Leukemia. Recent Progress and Future Directions, B. P. Gale, K. R. Rai. Liss., New York 1987; 373–381
   Google Scholar
• Kontoyianis D. P., Anaissie E. J., Bodey G. P. Infection in chronic lymphocytic leukemia: A reappraisal. Chronic Lymphocytic Leukemia. Scientific Advances and Clinical Developments, B. D. Cheson. Marcel Dekker Inc., New York 1993; 399–417
   Google Scholar
• Chapel H. M. Hypogammaglobulinemia and chronic lymphocytic leukemia. Chronic Lymphocytic Leukemia. Recent Progress and Future Directions, R. P. Gale, K. R. Rai. Liss., New York 1987; 383–389
   Google Scholar
• Rozman C., Montserrat E., Vinolas N. Serum immunoglobulins in B-CLL. Natural history and prognostic significance. Cancer 1988; 61: 279–283
   PubMed Web of Science ®Google Scholar
• Itäla M., Helenius H., Nikoskelaien J., Remes K. Infections and serum IgG levels in patients with chronic lymphocytic leukemia. Eur. J. Haematol. 1992; 48: 266–270
   PubMed Web of Science ®Google Scholar
• Catovsky D., Lauria F., Matutes E., et al. Increased T-lymphocytes in B-cell chronic lymphocytic leukemia. Br. J. Haematol. 1981; 47: 539–544
   PubMed Web of Science ®Google Scholar
• Kay N. Excessive T-cell subpopulation function in CLL: Excessive suppressor (Tγ) and defient (Tμ) activity with respect to B-cell proliferation. Blood 1981; 57: 418–420
   PubMed Web of Science ®Google Scholar
• Briggs P. G., Kraft N., Atkins R. C. T cells and CD45 expression in B-chronic lymphocytic leukemia. Leukemia Res. 1990; 14: 155–159
   PubMed Web of Science ®Google Scholar
• Apostopoulos A., Symeonidis A., Zoumbos N. Prognostic significance of immune function parameters in patients with chronic lymphocytic leukaemia. Eur. J. Haematol. 1990; 44: 39–44
   PubMed Web of Science ®Google Scholar
• Peller S., Kaufman S. Decreased CD45RA T cells in B-cell chronic lymphocytic leukemia patients: correlation with clinical stage. Blood 1991; 78: 1569–1573
   PubMed Web of Science ®Google Scholar
• Ziegler H. W., Kay N. E., Zarling J. M. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int. J. Cancer 1981; 27: 321–327
   PubMed Web of Science ®Google Scholar
• Heath M., Cheson B. D. Defective complement activity in chronic lymphocytic leukemia. Am. J. Haematol. 1985; 19: 63–73
   PubMed Web of Science ®Google Scholar
• Arnold C., McPhedran P. Prognostic significance of neutrophil counts, gammaglobulin levels and symptoms in chronic lymphocytic leukemia. Blood 1985; 66(Suppl. 1)170a
   Google Scholar
• De Rossi G., Mauro F. R., Ialongo P., Coluzzi S., Pizzo E. Monocytopenia and infections in chronic lymphocytic leukaemia. Eur. J. Haematol. 1991; 46: 119
   PubMed Web of Science ®Google Scholar
• Cheson B. D. Recent advances in the treatment of B-cell chronic lymphocytic leukemia. Oncology 1990; 4: 71–93
   PubMedGoogle Scholar
• Vadhan-Raj S., Velasquez W. S., Butler J. J., et al. Stimulation of myelopoiesis in chronic lymphocytic leukemia and in other lymphoproliferative disorders by recombinant human Granulocyte-Macrophage Colony-Stimulating Factor. Am. J. Haematol. 1990; 33: 189–197
   PubMed Web of Science ®Google Scholar
• Twomey J. J. Infections complicating multiple myeloma and chronic lymphocytic leukemia. Arch. Intern. Med. 1973; 132: 562–565
   PubMed Web of Science ®Google Scholar
• Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. N. Engl. J. Med. 1988; 319: 902–907
   PubMed Web of Science ®Google Scholar
• Osgood E. E. Treatment of chronic lymphocytic leukemias. Results of therapy by titrated, regularly spaced total body radioactive phosphorus or roentgen irradiation. J. Am. Med. Assoc 1952; 150: 1372–1379
   PubMed Web of Science ®Google Scholar
• Scott R. B. Chronic lymphocytic leukaemia. Lancet 1957; 1: 1162–1167
   Google Scholar
• Pisciotta A. V., Hirschbock J. S. Therapeutic consideration in chronic lymphocytic leukemia. Arch. Intern. Med. 1957; 99: 334–345
   Web of Science ®Google Scholar
• Ultman J. E., Fish W., Osserman E., Gellhorn A. The clinical implications of hypogammaglobulinemia in patients with chronic lymphocytic leukemia and lymphocytic lymphosarcoma. Ann. Intern. Med. 1959; 51: 501–516
   PubMed Web of Science ®Google Scholar
• Shaw R. K., Szwed C., Boggs D. R., et al. Infection and autoimmunity in chronic lymphocytic leukemia. Arch. Intern. Med. 1960; 106: 467–478
   Web of Science ®Google Scholar
• Hudson R. P., Wilson S. J. Hypogammaglobulinemia and chronic lymphocytic leukemia. Cancer 1960; 13: 200–204
   PubMed Web of Science ®Google Scholar
• Aroesty J. M., Furth F. W. Infection and chronic lymphocytic leukemia. A review of 61 cases. NY State J. Med. 1960; 62: 1946–1952
   Google Scholar
• Shaw R. K., Boggs D. R., Silberman H. R., Frei E., III. A study of prednisone therapy in chronic lymphocytic leukemia. Blood 1961; 17: 182–195
   Web of Science ®Google Scholar
• Boggs D. R., Sofferman S. A., Wintrobe M. M., Cos-Twright G. E. Factors affecting duration of survival of patients with chronic lymphocytic leukemia. Am. J. Med. 1966; 40: 243–254
   PubMed Web of Science ®Google Scholar
• Hansen M. M. Chronic lymphocytic leukemia. Clinical studies based on 189 patients followed for a long time. Scand. J. Haematol. 1973; 1–282, (Suppl. 18)
   Google Scholar
• Travade Ph., Dusart J. D., Cavaroc M., Beytout J., Rey M. Les infections graves associées a la leucemie lymphoide cronique. La Presse Med. 1986; 15: 1715–1718
   PubMedGoogle Scholar
• Montserrat-Costa E., Matutes E., Rozman C., et al. Infecciones en la leucemia linfoide cronica. SNGRA (San-gre) 1977; 22: 968–975
   Google Scholar
• Hill H. R. Infections complicating congenital immunodeficiency syndromes. Clinical Approach to Infection in the Compromised Host, R. H. Rubin, L. S. Young. Plenum Medical Book Company, New York 1981; 417–420
   Google Scholar
• Barrett A. Chronic indolent orofacial herpes simplex virus infection in chronic lymphocytic leukemia: A report of 3 cases. Oral Surg. 1988; 15: 387–390
   Google Scholar
• Case Records of the Massachusset General Hospital. Case 50–1992. N. Engl. J. Med. 1992; 327: 1801–1809
   PubMedGoogle Scholar
• Kaplan M. H., Rosen P. P., Armstrong D. Cryptococcosis in a cancer hospital. Cancer 1977; 39: 2265–2274
   PubMed Web of Science ®Google Scholar
• Kauffman C., Israel K., Smith J., White A., Schwarz J., Brooks C. Histoplasmosis in immunosup-pressed patients. Am. J. Med. 1978; 64: 923–932
   PubMed Web of Science ®Google Scholar
• Griffiths H., Brennan V., Lea J., Bunch C., Chapel H. M. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood 1989; 73: 366–368
   PubMed Web of Science ®Google Scholar
• Molica S. 1993, Unpublished results
   Google Scholar
• Fairley G. H., Scott R. B. Hypogammaglobulinemia in chronic lymphocytic leukemia. Br. Med. J. 1961; 4: 920–924
   Google Scholar
• Foa R. Pathogenesis of the immunodeficiency in chronic lymphocytic leukemia. Chronic Lymphocytic Leukemia: Scientific Advances and Clinical Developments, B. D. Cheson. Marcel Dekker Inc., New York 1993; 147–166
   Google Scholar
• Rundles R. W., Coonrad E. V., Arends T. Serum proteins in leukemia. Am. J. Med. 1954; 16: 842–853
   PubMed Web of Science ®Google Scholar
• Videbaek A. Some clinical aspects of leukemia. Acta Haematol. 1960; 24: 54–58
   PubMedGoogle Scholar
• Foa R., Catovsky D., Brozovic M., et al. Clinical staging and immunological findings in chronic lymphocytic leukemia. Cancer 1979; 44: 483–487
   PubMed Web of Science ®Google Scholar
• Ben-Bassat I., Many A., Modan M., Peretz C., Ra-Mot B. Serum immunoglobulins in chronic lymphocytic leukemia. Am. J. Med. Sci. 1979; 278: 4–9
   PubMed Web of Science ®Google Scholar
• Whelan C. A., Willoughby R., McCann S. R. Relationship between immunoglobulin levels, lymphocyte subpopulations and Rai staging in patients with B-CLL. Acta Haematol. 1983; 69: 217–223
   PubMed Web of Science ®Google Scholar
• Montserrat E., Marques-Pereira J. P., Gallart T., Rozman C. Bone marrow histopathology and immunologic findings in B-chronic lymphocytic leukemia. Cancer 1984; 54: 447–451
   PubMed Web of Science ®Google Scholar
• Dighiero G. Hypogammaglobulinemia and disordered immunity in CLL. Chronic Lymphocytic Leukemia: Scientific Advances and Clinical Developments, B. D. Cheson. Marcel Dekker Inc., New York 1993; 147–166
   Google Scholar
• Griffiths H., Lea J., Bunch C., Lee M., Chapel H. Predictors of infection in chronic lymphocytic leukemia (CLL). Clin. Exp. Immunol. 1992; 89: 374–377
   PubMed Web of Science ®Google Scholar
• Jaksic B., Rundek T., Planinc-Peraica A., Brugiatelli M. (1988) Changes of serum immunoglobulin concentration in B-chronic lymphocytic leukemia (B-CLL). XXII Congress of the International Society of Hematology, Milan, August-September, 28-21988, 323, Abstract book
   Google Scholar
• Keating M. J. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. Semin. Oncol. 1990; 17: 49–62
   PubMed Web of Science ®Google Scholar
• Ziegler-Heitbrock H. W. L., Schlag R., Flieger D., Thiel E. Favorable response of early stage B CLL patients treatment with IFN-alpha 2. Blood 1989; 73: 1426–1430
   PubMed Web of Science ®Google Scholar
• Ross S. C., Densen P. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in immune deficiency. Medicine (Baltimore) 1984; 63: 243–273
   PubMed Web of Science ®Google Scholar
• Miller D., Karnofsky D. A. Immunological factors and resistance to infection in chronic lymphocytic leukemia. Am. J. Med. 1961; 31: 748–757
   PubMed Web of Science ®Google Scholar
• Füst G., Czink E., Minh D., Miszlay Z., Varge L., Hollan S. R. Depressed classical complement pathway activities in chronic lymphocytic leukemia. Clin. Exp. Immunol. 1985; 60: 489–495
   PubMed Web of Science ®Google Scholar
• Dicato M., Schmit J. C, Mahon G., Ries F. Chronic activation of complement in chronic lymphocytic leukemia. Blood 1991; 78(Suppl. 1)464a
   Google Scholar
• Halt J. M., Witts L. J. Splenectomy in leukaemia and reticuloses. Q. J. Med. 1966; 35: 369–384
   PubMedGoogle Scholar
• Morris P. J., Cooper I. A., Madigan J. P. Splenectomy for haematological cytopenias in patients with malignant lymphomas. Lancet 1975; 2: 250–253
   PubMed Web of Science ®Google Scholar
• Ferrant A., Michaux I. L., Sokal G. Splenectomy in advanced chronic lymphocytic leukemia. Cancer 1986; 58: 2130–2135
   PubMed Web of Science ®Google Scholar
• Stein R. S., Weikert D., Reynolds V., Greer J. P., Flexner J. M. Splenectomy for end-stage chronic lymphocytic leukemia. Cancer 1987; 59: 1815–1818
   PubMed Web of Science ®Google Scholar
• Delpero J. R., Mouvenaeghe G., Gastant J. A., et al. Splenectomy for hypersplenism in chronic lymphocytic leukemia and malignant non-Hodgkin's lymphoma. Br. J. Surg. 1990; 77: 443–450
   PubMed Web of Science ®Google Scholar
• López-Guillermo A., Pereira A., Montserrat E., Roz-Man C. Esplenectomia en la leucemia linfänca crönica. Sangre 1988; 33(4)287–290
   PubMedGoogle Scholar
• Kay N., Kaplan M. E. Defective expression of T cell responsiveness in chronic lymphocytic leukemia: analysis of activation events. Blood 1986; 67: 578–584
   PubMed Web of Science ®Google Scholar
• Hautekeete M. L., De Bock R. F., Van Bockstaele D. R., Colpin G. C, Berneman Z. N., Peetermans M. E. Flow cytometric analysis of T-lymphocyte sub-populations in B-cell chronic lymphocytic leukemia: correlation with clinical stage. Blut 1987; 55: 447–452
   PubMedGoogle Scholar
• Palk B. F., Fox R., Brookrneyer R., et al. Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. N. Engl. J. Med. 1987; 16: 61–66
   Web of Science ®Google Scholar
• Wijermans P. W., Van Der Linden J. S. M., Gerrits W. B. J., Haak H. L. Severe immunodeficiency and opportunistic infections seen in patients treated with fludarabine monophosphate. Blood 1992; 80(Suppl. 1)46a
   PubMedGoogle Scholar
• Kay N. E., Howe R. B., Douglas S. D. Effect of therapy on T cell subpopulation in patients with chronic lymphocytic leukemia. Leukemia Res. 1982; 6: 345–352
   PubMed Web of Science ®Google Scholar
• McCann S. R., Whelan C. A., Breslin B., Temperley I. J. Lymphocyte subpopulations following splenic irradiation in patients with chronic lymphocytic leukemia. Br. J. Haematol. 1982; 50: 225–232
   PubMed Web of Science ®Google Scholar
• Lauria F., Raspadori D., Tura S. Effect of a thymic factor on T lymphocytes in B cell chronic lymphocytic leukemia: In vitro and in vivo studies. Blood 1984; 64: 667–669
   PubMed Web of Science ®Google Scholar
• Rozman C., Montserrat E., Rodriguez-Fernández J. M., et al. Bone marrow histologic pattern. The best single prognostic parameter in chronic lymphocytic leukemia. A multivariate analysis of 329 cases. Blood 1984; 64: 642–648
   PubMed Web of Science ®Google Scholar
• Reynolds C. W., Foon K. A. T-lymphoproli-ferative diseases and related disorders in humans and experimental animals: A review of the clinical, cellular and functional characteristics. Blood 1984; 64: 1146–1158
   PubMed Web of Science ®Google Scholar
• Broxmeyer H. E., Pahwa R., Jacobsen N., et al. Specific inhibitory activity against granulocyte-progenitor cells produced by non-T lymphocytes from patients with neutropenia. Exp. Haematol. 1980; 8: 278–286
   PubMed Web of Science ®Google Scholar
• Keating M. J., Kantarjian H., Talpaz M., Redman J., McCredie K. B. Fludarabine therapy in chronic lymphocytic leukemia. Nouv. Rev. Fr. Haematol. 1988; 30: 461–466
   PubMedGoogle Scholar
• Dillman R. O., Mick R., McLntyre O. R. Pen-tostatinein chronic lymphocytic leukemia: A phase II trial of Cancer and Leukemia Group B. J. Clin. Oncol. 1989; 7: 433–438
   PubMed Web of Science ®Google Scholar
• Miller D. G., Budinger J. M., Karnofsky D. A. A clinical and pathological study of resistance to infection in chronic lymphocytic leukemia. Cancer 1962; 15: 307–329
   PubMed Web of Science ®Google Scholar
• Plastoucas C. D., Hernandes G., Gupta S. L., et al. Defective spontaneous and antibody-dependent cytotoxicity mediated by E-rosette-positive and E-rosette-negative cells in untreated patients with chronic lymphocytic leukemia: Augmentation by in vitro treatment with interferon. J. Immunol. 1980; 125: 1216–1223
   PubMed Web of Science ®Google Scholar
• Foa R., Lauria F., Lusso P., et al. Discrepancy between phenotypic and functional features of natural killer T-lymphocytes in B-cell chronic lymphocytic leukemia. Br. J. Haematol. 1984; 58: 509–516
   PubMed Web of Science ®Google Scholar
• Villamor N., Reverter J. C, Montserrat E., Urbano-Is-Pizua A., Vives-Corrons J. L., Rozman C. Recombinant alpha-2b-interferon may restore natural-killer activity in patients with B-chronic lymphocytic leukemia. Leukemia 1992; 6: 547–552
   PubMed Web of Science ®Google Scholar
• Foa R., Fierro M. T., Lusso P., et al. Effect of alpha-interferon on the immune system of patients with hairy cell leukemia. Leukemia 1987; 1: 377–379
   PubMed Web of Science ®Google Scholar
• Foa R., Fierro M. T., Lusso P., et al. Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: Defective LAK generation and reduced susceptibility of leukemic cells to allogenic and autologous LAK effectors. Blood 1990; 76: 1349–1354
   PubMed Web of Science ®Google Scholar
• Semenzato G., Foa R., Agostini C., et al. High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia. Blood 1987; 70: 396–400
   PubMed Web of Science ®Google Scholar
• Molica S., Iorfida A., Dattilo A. (1991) Soluble IL-2 receptor in B-chronic lymphocytic leukemia. 2nd Vicenza International Workshop on Hematology “New Insights in Lymphomas”, Vicenza, May, 29–311991, 3, Abstract book
   Google Scholar
• Rubin L. A., Jay G., Nelson D. L. The released interleukin 2 receptor binds interleukin 2 efficiently. J. Immunol. 1986; 137: 3841–3846
   PubMed Web of Science ®Google Scholar
• Domzig W., Stadler B. M., Heberman R. B. Interleukin 2 dependence of human natural killer (NK) cell activity. J. Immunol. 1983; 130: 1970–1975
   PubMed Web of Science ®Google Scholar
• Sawitsky A., Rai K. R., Glidewell O., et al. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood 1977; 50: 1049–1059
   PubMed Web of Science ®Google Scholar
• Kempin S., Lee B. J., Thaler H. T., et al. Combination chemotherapy of advanced chronic lymphocytic leukemia: The M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone). Blood 1982; 60: 1110–1121
   PubMed Web of Science ®Google Scholar
• Montserrat E., Alcala A., Parody R., et al. Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil and prednisone versus cyclophosphamide, vincristine and prednisone. Cancer 1985; 56: 2369–2375
   PubMed Web of Science ®Google Scholar
• Keating M. J., Scouros M., Murphy S., et al. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. Leukemia 1988; 2: 2369–2375
   Google Scholar
• French Cooperative Group on Chronic Lymphocytic Leukemia. Long-term results of the CHOP regimen in stage C chronic lymphocytic leukemia. Br. J. Haematol. 1984; 73: 334–340
   Google Scholar
• Boldt D. H., Von Hoff D. D., Kuhn J. G., et al. Effects on human peripheral lymphocytes of in vivo administration of 9-β-arabinofuranosyl-2-fluoroadenine-5-mono-phosphate (NSC 312887), a new purine antimetabolite. Cancer Res. 1984; 44: 4661–4666
   PubMed Web of Science ®Google Scholar
• Robertson L., Huh Y., Hirsch-Ginsberg C, Kantarjian H., Keating M. J. Immunophenotypic assessment of response in CLL after fludarabine. Proc. Am. Soc. Clin. Oncol. 1990; 9: 205a
   Google Scholar
• Schilling P. J., Vadhan-Raj S. Concurrent cytomegalovirus and Pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 1990; 323: 833–834
   PubMed Web of Science ®Google Scholar
• Bastion Y., Coiffier B., Tigaud J. D., Espinouse D., Bryon P. A. Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia. Eur. J. Cancer 1991; 27: 671
   PubMed Web of Science ®Google Scholar
• Anaissie E., Kontoyiannis D. P., Kantarjian H., Etling L., Robertson L. E., Keating M. J. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann. Intern. Med. 1992; 117: 466–469
   PubMed Web of Science ®Google Scholar
• O'Dwyer P. J., Spiers A. S., Marsoni S. Association of severe and fatal infections and treatment with pentostatin. Cancer Treat. Rep. 1986; 70: 1117–1120
   PubMedGoogle Scholar
• Giblett E. R., Anderson J. E., Cohen F., Pollara B., Meuwissen H. J. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972; 2: 1067–1069
   PubMed Web of Science ®Google Scholar
• Ratech H., Bell W. H., Hirshhom R., et al. Effects of deoxycoformicin in mice. I: Suppression and enhanced in vivo antibody responses of thymus-dependent and independent antigens. J. Immunol. 1984; 131: 3071–3076
   Google Scholar
• Saven A., Carrera J. C, Carson A., Beutler E., Piro L. D. 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leukemia and Lymphoma 1991; 5(Suppl. 1)135–138
   Google Scholar
• Talpaz M., Rosenblum M., Kurzock R., Reuben J., Kantarjian H., Gutterman J. Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia: A pilot study. Am. J. Haematol. 1987; 24: 341–350
   PubMed Web of Science ®Google Scholar
• Kay N. E., Oken M. M., Mazza J. J., Bradley E. C. Evidence for tumor reduction in refractory and relapsed B-CLL patients with infusional interleukin 2. Nouv. Rev. Fr. Haematol. 1988; 30: 475–478
   PubMedGoogle Scholar
• Hertler A. A., Shlossman D. M., Borowitz M. J., et al. A phase I study of T101-riein: A chain immunotoxin in refractory chronic lymphocytic leukemia. J. Biol. Resp. Mod. 1988; 7: 97–113
   PubMedGoogle Scholar
• Mackie P. H., Crockson R. A., Stuart J. C-reactive protein for rapid diagnosis of infection in leukemia. J. Clin. Pathol. 1979; 32: 1253–1256
   PubMed Web of Science ®Google Scholar
• Cooper E. H., Bunning R., Illingwork S., Spati B., Chied J. A. Serial measurement of beta-2 microglobulin, acute phase proteins and ESR in non-Hodgkin's lymphomas and CLL. Biomedicine 1978; 29: 154–158
   PubMedGoogle Scholar
• Balfour H. H., Bean B., Laskin O. L., et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N. Engl. J. Med. 1983; 308: 1448–1453
   PubMed Web of Science ®Google Scholar
• Cone L., Uhr J. W. Immunological deficiency disorders associated with chronic lymphocytic leukemia and multiple myeloma. J. Clin. Invest. 1964; 43: 2241–2248
   PubMed Web of Science ®Google Scholar
• Jacobson D. R., Ballard H. S., Silber R., Ripps C. S., Smith J. A., Schiffman G. S. Antibody response to pneumococcal immunization in patients with chronic lymphocytic leukemia. Blood 1988; 72(Suppl. 1)205a
   Google Scholar
• Shapiro E. D., Berg A. T., Austrian R., et al. The protective efficacy of polyvalent pneumococcal polysacca-ride vaccine. N. Engl. J. Med. 1991; 325: 1453–1460
   PubMed Web of Science ®Google Scholar
• Gribabis D. A., Pangalis G. A., Boussiotis V. A., Hannoun C. Influenza vaccine in B-chronic lymphocytic leukemia patients. Blood 1992; 80(Suppl. 1)48a
   Google Scholar
• Dicato M., Chapel H., Gamm H., et al. Use of intravenous immunoglobulin in chronic lymphocytic leukemia. A brief review. Cancer 1991; 68(Suppl. 1)1437–1439
   PubMed Web of Science ®Google Scholar
• Besa E. C. Recent advances in the treatment of chronic lymphocytic leukemia: Defining the role of intravenous immunoglobulin. Semin. Haematol. 1992; 29(Suppl. 1)14–23
   PubMedGoogle Scholar
• Besa E. C. Use of intravenous immunoglobulin in chronic lymphocytic leukemia. Am. J. Hematol. 1984; 76: 209–218
   Web of Science ®Google Scholar
• Weeks J. C, Tierney M. R., Weinstein M. C. Cost effectiveness of prophylactic intravenous immunoglobulin in chronic lymphocytic leukemia. N. Engl. J. Med. 1991; 325: 81–86
   PubMed Web of Science ®Google Scholar
• Besa E. C., Klumpe D. Prophylactic immune globulin in chronic lymphocytic leukemia. N. Engl. J. Med. 1992; 326: 139, (letter).
   PubMed Web of Science ®Google Scholar
• Chapel H., Brennan V., Delson E. Immunoglobulin replacement therapy by self-infusion at home. Clin. Exp. Immunol. 1988; 73: 160–162
   PubMed Web of Science ®Google Scholar
• Ochs H. O., Fisher S. H., Virant F. S., Lee M. L., Kingdom H. S., Wedgwood R. J. Non-A, non-B hepatitis intravenous immunoglobulin. Lancet 1985; 1: 404–405
   PubMed Web of Science ®Google Scholar
• Lee M. L., Courter S. G., Tait D., Kingdom H. S. Long term evaluation of intravenous immune globulin preparation with regard to non-A, non-B hepatitis safety. Viral Hepatitis and Liver Disease, A. J. Zuck-Erman. Alan R. Liss., New York 1988; 596–599
   Google Scholar
• Mitra G., Wong M. F., Mozen M. M., McDouglas J. S., Levy J. A. Elimination of infectious retrovirus during preparation of immunoglobulins. Transfusion 1986; 26: 394–397
   PubMed Web of Science ®Google Scholar
• Molica S. Combined use of alpha-2b interferon, chlorambucil, and prednisone in the treatment of previously treated B-chronic lymphocytic leukemia patients. Am. J. Hematol. 1993; 43: 334–335
   Web of Science ®Google Scholar